Drug Profile

AT 7687

Alternative Names: AT-673; AT-7687

Latest Information Update: 04 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Antag Therapeutics
Class Antihyperglycaemics; Obesity therapies; Peptides
Mechanism of Action Gastric inhibitory polypeptide receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Obesity; Type 2 diabetes mellitus
Phase I Type 1 diabetes mellitus

Most Recent Events

19 Jul 2026 Phase-II clinical trials in Obesity (Combination therapy, Treatment-experienced) in USA (SC) (NCT07724340)
19 Jul 2026 Phase-II clinical trials in Type 2 diabetes mellitus (Combination therapy, Treatment-experienced) in USA (SC) (NCT07724340)
07 Jun 2026 Pharmacodynamics data from a preclinical trial in Obesity released by Antag Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com